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Introduction: The novel coronavirus disease 2019 (COVID-19) presents a challenge for healthcare 
providers in terms of diagnosis, management, and triage of cases requiring admission. 
Case Report: A 47-year-old male with symptoms suspicious for COVID-19, pulse oximetry of 93% 
on room air, and multifocal pneumonia was risk stratified and safely discharged from the emergency 
department (ED) despite having moderate risk of progression to acute respiratory distress syndrome. 
He had resolution of his symptoms verified by telephone follow-up. 
Conclusion: Various risk-stratifying tools and techniques can aid clinicians in identifying 
COVID-19 patients who can be safely discharged from the ED.  [Clin Pract Cases Emerg Med. 
2020;X(X):XXX–XXX]
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INTRODUCTION
An emerging challenge in the management of patients 
with coronavirus disease 2019 (COVID-19) symptoms 
involves the disposition of those with moderate risk for 
decompensation. Clinicians must grapple with the desire 
to be conservative with this novel disease entity and the 
bitter truth that hospital beds as well as life-saving resources 
are increasingly limited. A growing body of evidence has 
identified key clinical factors associated with increased 
morbidity for these patients (Table). There are in addition 
many clinical tools available to aid in the diagnosis and 
disposition of these patients. While data are still emerging 
and not all the tools are fully validated, the growing corpus 
of evidence as well as shared decision-making and ensuring 
follow-up are essential parts of safely dispositioning moderate-
risk patients. Here we present a case of a 47-year-old male with 
symptoms suspicious for COVID-19 and with moderate risk of 
progression to acute respiratory distress syndrome (ARDS) who 
was discharged home from our emergency department (ED). 
We discuss which factors contributed to a favorable outcome 
and how to apply this to patients on a larger scale.
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CASE REPORT
In March 2020, a 47-year-old man presented to a 
suburban New Jersey hospital at the national epicenter of 
the COVID-19 pandemic. The patient had no past medical 
history of known illness. He presented with a chief complaint 
of persistent fever for 14 days as well as productive cough, 
scant hemoptysis, sore throat, generalized body aches, and 
worsening shortness of breath. He was seen by his primary 
Table. Factors identified with morbidity and mortality in novel 
coronavirus disease 2019 patients.2,3,4,5
• Age > 65
• Comorbid conditions, i.e., diabetes mellitus, hypertension
• Lymphopenia
• Elevated D-dimer
• Elevated lactate dehydrogenase
• Elevated C-reactice protein
• Elevated erythrocyte sedimentation rate
• Elevated ferritin
• Low albumin
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What do we already know about this clinical 
entity? 
The novel coronavirus disease 2019 
(COVID-19) is a rapidly evolving clinical 
entity that causes a variety of pulmonary and 
inflammatory conditions of varying severity.
What makes this presentation of disease 
reportable? 
This case involves a patient suspicious for 
novel coronavirus and provides examples of 
clinical scoring systems and tools that assisted 
in a safe disposition.
What is the major learning point? 
Not every suspected COVID-19 patient who may 
decompensate need be admitted. Clinicians have a 
variety of tools that can assist in decision-making.
How might this improve emergency medicine 
practice? 
Clinicians should use both their acumen and 
gestalt as well as evidence-based clinical 
tools in their management and disposition of 
COVID-19 patients.
care provider and prescribed a five-day course of amoxicillin. 
His symptoms did not resolve, so he presented to the ED. He 
denied recent travel, exposure to positive COVID-19 patients, 
and any history of smoking. 
The patient’s vital signs included a temperature of 38.3° 
Celsius, a heart rate of 110 beats per minute, a blood pressure 
of 103/62 millimeters of mercury, and respiratory rate of 
21 breaths per minute. His oxygen saturation was 93% on 
room air.  He was overweight with a body mass index of 29.1 
kilograms (kg) per meter (m)² (normal range 18.5-24.9 kg/
m²). His physical exam was otherwise benign including a 
pulmonary exam with clear and equal breath sounds. Despite 
tachypnea, he showed no signs of respiratory distress. He 
additionally had no signs of dehydration, cardiovascular 
collapse, or rash. 
The leading diagnosis was for COVID-19 or another 
respiratory virus given the geographical area and timing of 
his presentation, and the patient received a chest radiograph 
(CXR), a COVID-19 test, and a respiratory pathogen panel 
(RPP). His RPP was negative for a host of common viruses, 
and the COVID-19 test had a processing time of several days. 
His CXR showed multifocal, patchy, airspace opacities at 
the bilateral lower lobes concerning for multifocal infectious 
pneumonitis (Image).
Given his oxygen saturation and his CXR, the team 
discussed with the patient and his wife his risk factors and the 
likelihood of progression to ARDS. At this point, the patient 
did not require supplemental oxygen. The team used shared 
decision-making and explained the risks of progression of 
his pneumonitis and the likelihood of COVID-19 infection, 
as well as the benefits of returning home and avoiding 
hospitalization. The patient and his wife were given strict 
return precautions for worsening symptoms, particularly 
worsening dyspnea, and quarantine instructions and 
precautions were reviewed at length.1 He was discharged 
home that day with azithromycin and an albuterol metered-
dose inhaler. Telephone follow-up was made by the same ED 
provider to check on the patient, who confirmed his symptoms 
had abated.
DISCUSSION
An important step for clinicians treating confirmed 
or suspected COVID-19 patients is to risk stratify them 
and generate a clinical picture with probability of illness 
progression. In terms of risk, this patient was under 65 years 
old with no medical comorbidities, two of the most important 
predictors of morbidity in COVID-19.2,4 Had his oxygen 
saturation been lower, or had there been signs of respiratory 
Image. Chest radiograph of the patient. Note bilateral patchy 
opacities, most prominently at periphery of the lung concerning for 
multifocal pneumonia (arrows).
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distress on physical examination, more laboratory values 
may have been obtained. Laboratory values associated with 
increased morbidity and mortality from COVID-19 include 
lymphopenia and elevated acute phase reactants (Table).2,3,4,5 
These, however, are not necessarily always indicated in the 
acute setting. 
His RPP was of limited clinical utility given the 
possibility of coinfection;5 however, his CXR was concerning, 
given that bilateral interstitial infiltrates are a common finding 
in COVID-19 patients.3,4,5 
After information-gathering, clinicians can combine 
the clinical picture with a variety of clinical tools. In 
critically ill patients with COVID-19 pneumonia, the 
sequential organ failure assessment score has been shown 
to correlate with mortality.6 The pneumonia severity index 
(PSI) has traditionally been used to predict risk in patients 
with community-acquired pneumonia, although it has not 
been exclusively validated for COVID-19 pneumonia.7 
Alternatively, a yet-to-be validated tool, initially developed 
for risk stratifying viral pneumonia in China, shows promise 
for application in COVID patients. It evaluates Multilobular 
infiltration, Lymphocytopenia, Bacterial coinfection, Smoking 
history, hyperTension, and Age greater than or equal to 60 
into the MuLBSTA score, an acronym of its composing 
parts.8 It can also be calculated with less information than the 
more detailed PSI, although it still requires a complete blood 
count to evaluate for lymphopenia. Each individual point on 
the score corresponds to a different 90-day mortality value. 
The cutoff between low-risk patients and high-risk patients 
is a score of 12, which corresponds to a 90-day mortality of 
16%. Had this patient had a normal white blood cell count, 
he would have received five points on his MuLBSTA score, 
corresponding to a 90-day mortality of 2.17%, which is rather 
high for a “low-risk” designation. Nevertheless, this tool may 
have helped reinforce what the physical exam, vital signs, and 
CXR already revealed: that this patient may yet deteriorate 
and require respiratory support.
Finally, what is the disposition?  Should we admit or 
discharge?  This often involves more gestalt than clinical 
science. The patient was a good candidate for discharge given 
his likelihood of convalescing and healing, his ability to 
understand the risks of discharge, his ability to return should 
symptoms progress, his social network which was capable of 
offering him support and, most importantly, the ability of the 
emergency physician to contact him and follow up. It is also 
essential that this decision be shared between the clinician and 
the patient and that the clinician stresses the risks and benefits 
of hospitalization. Ultimately, the shared conversation and 
education of the patient and the ability to follow-up are the 
most essential factors in discharging moderate risk patients.
CONCLUSION
The patient in our case had moderate-risk COVID-19 but 
had resolution of symptoms without the need for supplemental 
oxygen therapy or hospital admission. Key contributing 
factors to positive outcomes include strict return precautions 
and a follow-up plan. However, not all cases of COVID-19 
will resolve. Patients may return at the threshold of intubation, 
or with new, unpredicted clinical manifestations of this 
novel virus. Clinicians must be prepared to accept a degree 
of uncertainty with the risk of a bounceback return to the 
ED. These risks should be discussed with patients and their 
preferred support system. In the setting of a global pandemic 
where ventilators and beds are numbered, a bounceback 
should not be viewed as a failure of care. Instead, thoughtful 
disposition of moderate-risk COVID-19 discharges should be 
seen as temporizing measures to best use our resources. In a 
practical setting, this may mean the difference between life or 
death for a patient. 
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